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Introduction
Rates of HIV/HCV co-infection vary between countries, but
globally 20–30% of the 34 million HIV-infected people are
estimated to have chronic HCV infection, reﬂecting shared
transmission routes in both infections [1,2]. HIV/HCV
co-infection increases the risk and progression of liver
disease [3,4], and even in the era of highly active antiretroviral
therapy (ART), HIV infection remains an independent risk factor
for advanced liver disease in co-infected patients [5,6]. Adult
studies have shown that chronic HCV co-infection, via immune
activation and chronic inﬂammation, contributes to excessive
rates of extrahepatic illnesses, including cardiovascular disease,
cancers, renal and bone disorders, and to higher overall and
liver-related mortality in HIV-infected individuals [7–11].
HCV co-infection among children living with HIV is less prevalent
than among adults. Most children with HIV/HCV co-infection in
Europe acquired this vertically from co-infected mothers, with
estimated mother-to-child transmission (MTCT) rates of both
viruses of 4–10% [12]; however, there are groups of children and
adolescents who acquired HIV/HCV co-infection nosocomially
or behaviourally [13–15]. There are limited data on HCV disease
progression in HIV/HCV co-infected children [16,17]. Recent
results from the European Pregnancy and Paediatric HIV Cohort
Collaboration (EPPICC) showed that half of children and
adolescents had raised liver function test results at their most
recent visit, 12% had advanced ﬁbrosis as measured by liver
biopsy or transient elastography (TE) [17], suggesting that a
substantial proportion of HIV/HCV co-infected youth warrant
treatment for HCV disease.
Despite the very rapid development of new direct-acting antiviral
(DAA) agents against HCV, which has revolutionised HCV
treatment in adults [18], there has been signiﬁcant delay in their
evaluation in the paediatric population, and no DAAs to date have
been approved for use in children. Thus, in HCV-infected children
combination treatment with pegylated interferon alpha 2a or 2b
and ribavirin (peg-IFN/RBV) remains the standard of care.
In HCV mono-infected children, sustained virological response
(SVR) rates at 24 weeks after treatment completion (SVR24) with
peg-IFN/RBV are reported to be consistently higher compared to
adults [19]. Studies of HIV/HCV co-infected adults have
reported lower rates of successful treatment outcomes with
peg-IFN/RBV than seen in mono-infected adults [20,21]. The
data in co-infected children are conﬁned to small case
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Abstract
Objectives: To describe use of treatment for chronic hepatitis C virus (HCV) infection in HIV/HCV co-infected children
and young people living in Europe and to evaluate treatment outcomes.
Methods: HCV treatment data on children and young people aged <25 years with HIV/HCV co-infection were collected
in a cohort collaboration of 11 European paediatric HIV cohorts. Factors associated with receipt of HCV treatment and
with sustained virological response 24 weeks after treatment completion (SVR24) were explored.
Results: Of 229 HIV/HCV co-infected patients, 22% had a history of AIDS and of 55 who were treated for HCV, 47 (85%)
were receiving combined antiretroviral therapy. The overall HCV treatment rate was 24% (n=55) but it varied substantially
between countries, with the highest rate being in Russia at 61% (30/49). Other factors associated with treatment receipt
were older age [adjusted odds ratio (AOR) 5.24, 95% conﬁdence interval (CI) 1.9–14.4, for 18—24-year-olds vs 11–17-
year-olds, P=0.001] and advanced ﬁbrosis (AOR 5.5, 95% CI 1.3–23.7; for ≥9.6 vs ≤7.2 kPa, P=0.02). Of 50 patients with
known treatment outcomes, 50% attained SVR24. Of these, 16 (80%) had genotype (GT) 2,3 and 8 (29%) had GT 1,4
(P<0.001). After adjusting for genotype (GT 1,4 vs GT 2,3), females (P=0.003), patients with non-vertical HCV acquisition
(P=0.002) and those with shorter duration of HCV (P=0.009) were more likely to have successful treatment outcomes.
Conclusion: Only half of the HIV/HCV co-infected youth achieved an HCV cure. HCV treatment success appears to be
lower in the context of HIV co-infection than in HCV mono-infection, underscoring the urgent need to speed up approvals
of new direct-acting antiviral combinations in children.
Keywords: HCV/HIV co-infection, pegylated interferon, ribavirin, children, young people
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series [16,22,23], and thus important questions remain with
respect to coverage and response to what is currently considered
a standard treatment for HCV in this population.
In this study we describe treatment uptake in HIV/HCV
co-infected children and young people in a European cohort
collaboration and evaluate treatment outcomes and factors
associated with successful outcomes.
Methods
In 2012–2013 we conducted a retrospective cross-sectional
cohort study within 11 European paediatric HIV cohorts from 10
countries participating in EPPICC (see acknowledgements).
EPPICC performs epidemiological research on the prognosis and
outcome of HIV-infected pregnant women, HIV-infected children
and children exposed to HIV in utero using data captured from
cohorts through routine data collection, and is part of the
EuroCoord network (www.eurocoord.net).
Participants
All children and young people with chronic HCV co-infection
acquired vertically or in childhood aged >18 months and
<25 years at last follow-up were eligible for inclusion.
The data were collected according to the standard HIV Cohorts
Data Exchange Protocol (www.hicdep.org) and additional
case-note review for HCV-speciﬁc variables, with a modiﬁed
HICDEP table for these variables. Variables included
socio-demographics, use of antiretroviral drugs, HIV clinical
status, HIV RNA levels, CD4 cell counts and percentages, HCV
genotype (GT), HCV disease status, anti-HCV treatment and liver
investigations (ALT, AST, liver biopsy, TE).
Deﬁnitions
HIV disease was categorised using CDC 1994 [24] or WHO
2007 [25] classiﬁcations, depending on which classiﬁcations were
routinely used in the participating cohorts; for the analysis, CDC
A and WHO 1,2; CDC B and WHO 3; and CDC C and WHO 4
were grouped together. HIV immunological stage was categorised
using CDC 2014 classiﬁcation [26].
No or mild ﬁbrosis was deﬁned as METAVIR score F0–F1,
moderate ﬁbrosis as METAVIR score F2, and advanced ﬁbrosis as
METAVIR score F3–F4, evaluated by liver biopsy [27,28]. In
children who had TE only (and no biopsy), advanced ﬁbrosis was
deﬁned as liver stiffness of ≥9.6 kPa [29].
Duration of HCV infection was calculated as the time between
the presumed date of infection and date of last study visit. For
patients with reported vertically acquired HCV, birth date was
used as the date of HCV infection; for participants with other
modes of acquisition, the date of HCV diagnosis was used as a
proxy for date of infection.
Successful outcome was deﬁned as sustained virological response
24 weeks after the end of treatment (SVR24). In treatment
outcome analysis HCV GT 1 and GT 4 were grouped together as
‘hard to treat’ with peg-IFN/RBV, and GT 2 and GT 3 deﬁned as
‘easier to treat’ [19].
Adverse events were rated using the Division of AIDS (DAIDS)
classiﬁcation for grading the severity of adverse events [30]. The
upper limit of normal (ULN) cut-off for AST and ALT was deﬁned
as 40 IU/L.
Statistical analysis
Univariable comparisons were assessed with the chi-squared test
for categorical variables. Logistic regression modelling was used
to identify factors associated with receipt of HCV treatment.
Controlling for GT groups (‘hard to treat’ and ‘easier to treat’), the
relationship between SVR24 and other explanatory variables,
including age, sex, CD4 cell count, HIV viral load, mode of HCV
acquisition, duration of HCV infection and liver ﬁbrosis evaluated
by TE were examined using a Cochran–Mantel–Haenszel analysis.
Statistics were conducted using SAS version 9.3 (SAS Institute
Inc, Cary, NC, USA).
Ethical approval
Individual cohorts followed their local ethics approval procedures
for this secondary analysis of retrospective data.
Results
There were 229 children and young people with HIV/HCV
co-infection included in the study, with a median age at last
follow-up of 16.2 years [interquartile range (IQR) 10.0–20.2].
There were three participants from Belgium, one from Germany,
20 from Italy, four from Poland, 33 from Romania, 49 from Russia,
three from Switzerland, 46 from Spain, three from the UK and 67
from Ukraine. The GT distribution was GT 1: 101 (44%); GT 2: 5
(2%); GT 3: 57 (25%); GT 4: 21 (9%); and GT unknown 45
(20%). A total of 55 (24%) children and young people had
received HCV treatment (peg-IFN/RBV).
HCV treatment uptake
Uptake of HCV treatment varied between countries. No
treatment was given in Germany, Poland, Romania, Switzerland,
the UK or Ireland. Among the countries where patients received
peg-IFN/RBV, treatment rates were 61% (30/49) in Russia, 37%
(6/16) in Italy, 33% (1/3) in Belgium, 26% (12/46) in Spain and
9% (6/67) in Ukraine. There was a signiﬁcant association
between age group and HCV treatment receipt, with 15%
(10/67) of patients aged 10 years or less, 10% (7/67) aged
11—17 years and 40% (38/95) aged 18–24 years having been
treated (P<0.0001). Nearly half of the patients with unknown
mode of HCV acquisition had received treatment (44%, 14/32),
compared with 20% (29/142) in vertically infected and 20%
(8/40) in nosocomially infected patients, and 27% (4/15) in
patients who injected drugs (P=0.03). A slightly higher
proportion of patients with GT 2,3 were treated than those with
GT 1,4: 35% (22/62) versus 25% (31/122), respectively
(P=0.15). Among the 95 patients with TE results available, 42%
(27/64) with liver stiffness ≤7.2 kPa were treated, while 47%
(9/19) of those with liver stiffness 7.3–9.5 kPa and 67% (8/12)
with advanced ﬁbrosis (≥9.6 kPa) were treated (P=0.29).
In adjusted logistic regression analysis, including liver ﬁbrosis
stage (evaluated by TE), mode of acquisition, GT group and age
group (n=184), factors associated with increased probability of
HCV treatment were older age [adjusted odds ratio (AOR) 5.24,
95% conﬁdence interval (CI) 1.9–14.4, for young people aged
18–24 years vs children aged 11–17 years, P=0.001] and
advanced ﬁbrosis (AOR 5.5, 95% CI 1.3–23.7, for ≥9.6 vs
≤7.2 kPa, P=0.02); patients with easier-to-treat GT were more
likely to be treated than those with GT 1,4 (AOR 2.1, 95% CI
0.97–4.6, P=0.06).
Characteristics of treated children and young people
Socio-demographic and HIV-related characteristics of the 55
treated patients are presented in Table 1. Most were on ART
(n=47, 85%) with undetectable HIV RNA viral load (n=40, 73%)
and 60% n=33 had a CD4 cell count ≥500 cells/mm3 at their
most recent visit. HCV-related characteristics, including type of
treatment, are presented in Table 2. Over half of those treated
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biopsy in one patient) prior to treatment start and probability of
achieving an SVR24, although liver ﬁbrosis data were only
available for a subset of treated patients (71%, 34/48). After
additional adjustment for duration of HCV infection (classiﬁed
as <10/≥10 years), the probability of achieving SVR24 remained
signiﬁcantly associated with female gender (P=0.0097) and with
non-vertical mode of HCV acquisition (P=0.0009).
Discussion
Overall, a quarter of children and youth living with HIV and HCV
co-infection had received HCV treatment with peg-IFN/RBV,
with use of treatment varying widely across European cohorts. In
general, cohorts with the largest numbers of HIV/HCV
co-infected patients had the highest coverage with HCV
treatment. Clinical guidelines recommend treatment to be
considered for children with chronic HCV infection where there
are persistently elevated liver enzymes and/or evidence of liver
ﬁbrosis [31]. We found that children and young people in our
study were signiﬁcantly more likely to be treated if they had
evidence of advanced ﬁbrosis. Other factors associated with
receipt of peg-IFN/RBV were being older than 18 years and
having an ‘easier-to-treat’ genotype.
These treatment rates need to be interpreted in the context of
historically low HCV treatment rates in adults with HIV/HCV
Table 1. Patient demographics and HIV-related characteristics
Characteristic Overall (n=55)*
n (%) or median [IQR]
Age at most recent visit (years) 17.2 [9.9–22.2]
Female 38 (69)
White ethnicity 47 (85)
Country of residence
Russia 30 (55)
Spain 12 (22)
Italy 6 (11)
Ukraine 6 (11)
Belgium 1 (2)
History of AIDS 12 (22)
Median nadir CD4 count (cells/mm3), n=35 312 [222–406]
CD4 count at the last visit (cells/mm3), n=40 579 [356–750]
On ART at last visit 47 (85)
Undetectable HIV RNA at last visit, n=54 40 (74)
HIV clinical staging, n=52
CDC A/WHO 1 or 2 14 (27)
CDC B/WHO 3 28 (54)
CDC C/WHO 4 10 (19)
IQR, interquartile range; ART, antiretroviral therapy;  CDC, Centers for
Disease Control and Prevention; WHO, World Health Organization
* Unless stated otherwise
Table 2. HCV-related characteristics and treatment
Characteristic Overall (n=55)*
n (%) or median [range]
Mode of HCV acquisition
MTCT 29 (53)
Nosocomial 4 (7)
IDU 8 (15)
Other/unknown 14 (25)
HCV genotype
GT 1 28 (51)
GT 2 1 (2)
GT 3 21 (38)
GT 4 3 (5)
Unknown 2 (4)
ALT prior to HCV treatment (IU/L), n=27
Normal 7 (26)
DAIDS grade 1 12 (44)
DAIDS grade 2 7 (26)
DAIDS grade 3 1 (4)
AST prior to HCV treatment (IU/L), n=25
Normal 11 (44)
DAIDS grade 1 12 (48)
DAIDS grade 2 2 (8)
TE prior to HCV treatment (kPa), n=34
≤7.2 20 (58)
7.3–9.5 9 (26)
9.6–12.5 4 (12)
≥12.6 1 (3)
HCV treatment
Peg-IFN α 2a/RBV 29 (53)
Peg-IFN α 2b/RBV 22 (40)
Unknown 4 (7)
Median duration of treatment (weeks) 47 [8–82]
GT, genotype; IDU, intravenous drug use; MTCT, mother-to-child
transmission; peg-IFN, pegylated interferon; RBV, ribavirin;
TE, transient elastography
* Unless stated otherwise
had GT 1 and 28% had GT 3 infection. Most patients (n=38,
69%) were aged 18 years or older at the initiation of treatment
for HCV.
ALT and/or AST measurements prior to HCV treatment initiation
were available for a subset of patients: 74% (20/27) had ALT
levels above the ULN and 56% (14/25) had AST levels above
ULN (Table 2). Results of TE prior to starting or during treatment
were available for 34 of the treated patients, indicating that 15%
had advanced ﬁbrosis or cirrhosis (Table 2). Four patients had
results of liver biopsy available prior to treatment; of these three
had no or mild ﬁbrosis and one advanced ﬁbrosis.
At treatment start, the median duration of HCV infection was
18 years for vertically infected patients (IQR 10–20 years) and
4 years for the non-vertically infected (IQR 1.7–8.9 years).
Patients were initiated on treatment with standard doses as per
prescribing information for peg-IFN α-2a, peg-IFN α-2b and
ribavirin. The median duration of treatment, independently of
HCV genotype, was 47 weeks (range 8–82). There were 11
discontinuations of treatment, all in patients with GT 1,4, with
median duration at discontinuation of 20 weeks (range 8–37).
HCV treatment outcomes
The virological outcomes at 24 weeks after the end of treatment
were available in 50 of 55 patients (91%) at the time of analysis.
Of these, 25 (50%) achieved SVR24 (Figure 1). The SVR24 rates
were 29% (8/28) for GT 1,4 and 80% (16/20) for GT 2,3
(P<0.001). Of the eight patients with advanced liver ﬁbrosis
(6 GT 1, 1 GT 3, 1 GT 4), only one achieved SVR24. SVR24 was
not associated with AIDS history: 36% (4/11) with AIDS vs 54%
(21/39) without AIDS (P=0.15) or median nadir CD4 cell count
(P=0.27).
Females, patients with non-vertical HCV acquisition and those
with shorter duration of HCV infection were more likely to have
successful treatment outcomes after adjusting for GT groups
(GT 1,4 vs GT 2,3) (Table 3). There was no association between
liver ﬁbrosis stage (measured by TE in most patients and liver
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co-infection. The latter reﬂects a range of factors including
contraindications, poor adherence to HIV treatment, cost and
patient choice. In the HEPVIH study, a French cohort of
HIV/HCV co-infected adults, 40% of those eligible for HCV
treatment started therapy during 2005–2011. HCV treatment
initiation was associated with good adherence to HIV drugs and
Only half of the HIV/HCV co-infected youth who received HCV
treatment achieved SVR24, with rates of 29% for GT 1,4 and 80%
for GT 2,3. A meta-analysis of eight trials of peg-IFN/RBV for
treatment of HCV mono-infection reported that overall, 58% of
children achieved an SVR24 (52% with GT 1,4 and 89% with
GT 2,3) [19]. In a recent retrospective review of children with
chronic HCV treated in three UK paediatric liver centres between
2005 and 2010, 76% achieved SVR24 overall: 65% with GT 1 and
89% with GT 2 or GT 3 [36]. Thus, cure rates in our HIV/HCV
co-infected population seem particularly low for children with
‘hard-to-treat’ GT 1 and 4. This is consistent with ﬁndings for
adults with HIV/HCV co-infection, where cure rates for those
with GT 1,4 treated with peg-IFN/RBV were 25–40% [37].
We show that unsuccessful treatment outcomes were also more
frequently seen in children and young people with vertically
acquired HCV and in those with prolonged duration of HCV
infection, highlighting the need for early treatment in these
groups. Studies in adults demonstrated higher efﬁcacy of
IFN-based treatments with shorter duration of HCV infection. In
children this association has not been demonstrated, probably
due to relatively short duration of the infection and
absence/lower prevalence of comorbidities (co-infection,
intravenous drug use, alcohol, obesity) compared with adults.
With regard to the mode of HCV acquisition, our results agree
with the previously published data in HCV-mono-infected
children. In the study by Jara et al., treatment was particularly
effective in patients with parenterally acquired infection, although
statistical signiﬁcance was not reached, probably due to the small
number of enrolled patients [38]. A similar tendency was
demonstrated by Wirth et al. [39] and by Tajiri et al. [40].
Table 3. Factors associated with treatment outcome by HCV genotype groups
Characteristic Overall (n=48)
GT 1,4 (n=28) GT 2,3 (n=20) P value
SVR24 No SVR24 SVR24 No SVR24
Age, years n=28 n=20
<11 1 4 1 2 0.119
11–17 0 2 3 0
18–24 7 14 12 2
Gender
Male 0 10 2 2 0.003
Female 8 10 14 2
CD4 count before HCV treatment n=21 n=17
(cells/mm3)
200–499 4 4 6 0 0.07
≥500 3 10 8 3
Mode of HCV acquisition n=28 n=20
Vertical 1 13 5 4 0.002
Other 7 7 11 0
TE prior to HCV treatment (kPa) n=20 n=14
≤7.2 5 5 7 2 0.16
7.3–9.5 2 3 2 2
≥9.6 0 5* 1 0
Duration of HCV infection (years) n=28 n=19
<1 1 1 2 0 0.009
1–4.9 2 3 7 0
5–9.9 1 2 2 2 
10–14.9 4 6 2 0 
15–19.9 0 4 1 0 
≥20 0 4 1 2 
* One patient without TE prior to starting HCV treatment but with a pre-treatment liver ﬁbrosis
METAVIR F3 evaluated by liver biopsy is included in this group
was less frequent in patients with children
and in those with cardiovascular disease or
respiratory distress [32]. In the EuroSIDA
cohort, of nearly 2000 co-infected patients,
25% had received HCV therapy up to 2009,
with signiﬁcant increases in treatment
incidence over time, although the
researchers identiﬁed that around 20% of
untreated patients had indications for
treatment based on ﬁbrosis stage [33]. With
respect to treatment of children living with
chronic HCV, data on coverage in Europe are
limited. In an Italian multi-centre study of
HCV-infected children followed for an
average of 11.5 years, a quarter had received
treatment [34]; HCV treatment coverage in
Italian children with HIV/HCV co-infection
here was somewhat higher at 37%. In a
national paediatric referral centre in the UK
treatment rates were 60% over the period
1990–2008 [35].
Despite that a high proportion of co-infected
children and adolescents in EPPICC cohorts
had evidence of liver disease, and HCV liver
disease progression is recognised to be
accelerated in HIV/HCV co-infection, only
a quarter of co-infected patients were
treated. Although not investigated in this
study, the possible reasons for the low
treatment uptake were likely to be related to
inconvenient administration (e.g. using
injectables), long treatment duration,
associated toxicities and anticipated poor
response.
Figure 1. Proportion of subjects treated for HCV and HCV treatment outcomes by
HCV genotype (total n=299)
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Our study showed a higher SVR24 rate among female patients.
Gender differences in natural history and treatment response have
been reported previously, including higher rates of spontaneous
clearance in females [41], higher vertical transmission rates for
girls [42] and higher SVR rates with peg-IFN/RBV in females
compared to males [43]; the reasons are not well understood but
may reﬂect both biological and behavioural factors (e.g.
medication adherence).
With DAAs for paediatric use on the horizon, it is likely that
‘warehousing’ of paediatric patients with HCV (including those
with HIV co-infection) may now be occurring. However, for
co-infected children with GT 2,3, where high rates of SVR24 can
be achieved with peg-IFN/RBV, some clinicians and parents
(particularly those who have themselves achieved a cure for GT 2
or 3 disease) may not wish to delay treatment for their children
owing to the uncertain timelines for paediatric access to DAAs.
This may particularly be the case in light of the known impact of
HIV on accelerating HCV disease and the growing evidence to
indicate that liver ﬁbrosis progresses during childhood: in a study
of 44 children from the PEDS-C trial, with biopsies on average
6 years apart, 30% showed an increase in severity of ﬁbrosis and
the proportion of patients with bridging ﬁbrosis/cirrhosis
increased from 11% to 20% [44].
The new DAAs provide high cure rates, exceeding 95%, and all
studies to date have shown SVR24 rates among HIV/HCV
co-infected individuals to be the same or better than those
among HCV mono-infected people [45]. There is an urgent need
to combine efforts of clinicians, community, pharmaceutical
companies and regulatory authorities to speed up approvals of
the new DAA combinations in the paediatric population. When
the new regimens acquire paediatric approval, HIV/HCV
co-infected children should be considered a priority group for
the new treatments.
There are some limitations to this study. The study had a
cross-sectional design and given the observational nature of the
study, there were missing data for some patients. There were 11
treatment discontinuations, but due to the retrospective nature
of the study we were not able to ﬁnd the reasons for
discontinuations, and therefore cannot comment on
discontinuations secondary to toxicity. Transient elastography
data, and therefore most of the data on the stage of liver disease,
should be interpreted with caution as the method has not been
validated for children with hepatitis C. The duration of HCV
infection for patients with non-vertically acquired HCV is likely to
be underestimated as it was calculated as the interval between
the presumed date of infection and date of last study visit.
Therefore the association between HCV treatment outcomes and
the duration of HCV infection may be less pronounced than
reported. Treatment outcome data were not available for ﬁve
patients, for whom SVR24 was not yet available at the time of
analysis. No data were collected on IL-28 polymorphisms due to
rarity of measuring this in our population.
This is the largest study to date describing HCV treatment
outcomes with peg-IFN/RBV in HIV/HCV co-infected youth
with wide data capture across a number of European countries. In
the future, when the new DAAs become available for children,
there is potential to cure paediatric HCV in the vast majority of
children.
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